大韓民国での筋萎縮性側索硬化症治療に最適なクリニックと費用をご発見ください2026

South Korea offers Neuronata-R, the world first licensed stem cell therapy for ALS. This autologous mesenchymal stem cell treatment is currently only available at specialized Korean university hospitals. It aims to slow disease progression through intrathecal injections into the spinal fluid.

• Arterial delivery: RE:YOUTH clinic uses arterial methods for 100% direct organ targeting during therapy.
• Integrative medicine: Specialized centers combine Parkinson-level care with bee-venom pharmacopuncture and herbal decoctions.
• Specialized facilities: Hanyang University Medical Center operates a dedicated clinic focused strictly on ALS.
• Regional standards: Korean protocols maintain higher tracheostomy rates for improved late-stage respiratory management.

Bookimed Expert Insight: While many countries offer experimental stem cell treatments, South Korea stands out because Neuronata-R is officially licensed for clinical use. Facilities like RE:YOUTH specialize in arterial delivery to ensure cells reach target organs. This regulatory approval provides a level of official oversight rarely found in other global stem cell hubs.

Patient Consensus: Patients note that while Korean clinics offer fast access to new treatments, the logistical effort is high. They suggest prioritizing established hospitals over smaller clinics to ensure comprehensive multidisciplinary support and genuine clinical trials.

South Korean tertiary hospitals provide specialized amyotrophic lateral sclerosis (ALS) care through dedicated clinics and multidisciplinary teams. Leading centers like Hanyang University Hospital and Severance Hospital integrate neurology, rehabilitation, and respiratory support. These institutions also offer innovative treatments including stem cell therapy and plasmapheresis.

• Hanyang University Hospital: Opened Koreas first dedicated ALS clinic with significant clinical research experience.
• Severance Hospital: This JCI-accredited facility manages 1.6 million outpatients annually using advanced AI.
• Asan Medical Center: Offers comprehensive neurological evaluations and participates in global ALS multi-center studies.
• RE:YOUTH Yonsei BH: Specializes in arterial stem cell therapy to deliver cells directly to organs.

Bookimed Expert Insight: Hospital volume is a key indicator of diagnostic precision in Korea. Severance Hospital manages over 1.6 million outpatients annually. Dr. Yeon Jung Kim at Asan Medical Center brings international experience from New York Presbyterian. These high-volume centers often provide access to government programs that reduce out-of-pocket patient costs.

Patient Consensus: Patients emphasize reaching out to specialized neurology departments at major Seoul centers to confirm multidisciplinary team availability. Many note that connecting with local patient advocacy groups helps navigate the specific care pathways in South Korea.

International health insurance rarely covers NeuroNata-R or stem cell injections in South Korea. Insurers typically classify these regenerative therapies as experimental or investigational. While South Korea conditionally approved NeuroNata-R for ALS, it lacks full approval from the United States Food and Drug Administration.

• Experimental status: Insurers deny most claims for regenerative therapies lacking full FDA approval.
• Local coverage: The South Korean National Health Insurance system does not cover NeuroNata-R.
• Standard care: Established procedures like bone marrow transplants for blood cancers are usually covered.
• Clinic documentation: Centers like RE:YOUTH provide documentation to help patients seek possible reimbursement.

Bookimed Expert Insight: Patient volume data suggests many travel to South Korea for arterial stem cell delivery. This method, available at clinics like RE:YOUTH, targets organs directly rather than using traditional IV. Doctors like Dr. Byung-hee Lee focus on this precision, yet patients should still plan for out-of-pocket costs.

Patient Consensus: Patients note that while the medical bureaucracy is complex, having detailed clinical reports in English is vital. They often emphasize that navigating these costs alone is the most stressful part of the journey.

Palliative care for ALS in South Korea emphasizes intensive medical interventions within tertiary hospitals. Practices prioritize invasive airway management and procedural nutrition support. Approximately 35% of patients undergo tracheostomy. This rate is significantly higher than in most Western healthcare systems.

• Tracheostomy usage: Roughly 32.2% of patients utilize ventilators within 24 months of diagnosis.
• Airway transitions: Respiratory care often moves rapidly from non-invasive masks to invasive surgical methods.
• Gastrostomy support: About 26.6% of patients receive Percutaneous Endoscopic Gastrostomy (PEG) for nutrition.
• Multidisciplinary teams: Specialized teams including dietitians and pharmacists manage complex enteral feeding protocols.

Bookimed Expert Insight: Clinical data reveals South Korea serves as a major hub for complex neurology. Severance Hospital alone manages 1.6 million outpatients annually. This high volume supports a massive infrastructure for technical interventions like tracheostomies. However, ALS is not currently eligible for formal hospice benefits under Korean law. Patients often transition to high-capacity centers like Gachon University Gil Medical Center for advanced support.

Patient Consensus: Patients note that family members often lead daily care for feeding tubes after discharge. Most local discussions regarding long-term management occur on Korean-language medical forums rather than international platforms.

Standard evaluations for ALS in South Korea typically require 1 week. Treatment cycles vary by protocol, with single stem cell therapy cycles lasting 9 to 10 days. Advanced protocols or drug infusions like Edaravone often require stays of 10 to 14 days per session.

• Diagnostic evaluation: Standard workups including EMG, NCV, and MRI take approximately 1 week.
• Stem cell cycle: One cycle of autologous stem cell therapy typically takes 9 to 10 days.
• Infusion cycles: Edaravone treatment cycles generally require 10 to 14 days of supervised infusions.
• Extended protocols: Patients receiving multiple injections may stay 4 to 12 weeks or return later.

Bookimed Expert Insight: While major centers like Severance Hospital manage massive patient volumes, specialized clinics focus on specific delivery methods. RE:YOUTH Clinic uses a targeted arterial injection method for stem cell therapy. This emphasizes that treatment time is not just about the drug used. It depends on the complexity of the delivery technology available at the clinic.

Patient Consensus: Patients note it is helpful that major centers have dedicated international teams. These coordinators help speed up the process so evaluations start immediately upon arrival.

South Korean hospitals provide comprehensive remote follow-up for ALS patients using advanced telemedicine and electronic health record systems. Facilities like Severance Hospital utilize digital imaging and smart building technology to monitor recovery. Patients receive detailed bilingual documentation and instructions to ensure seamless care continuity with local physicians.

• Telemedicine integration: Severance Hospital uses artificial intelligence and telemedicine for efficient remote patient consultations.
• Digital monitoring: Electronic health records (EHRs) allow doctors to track patient progress from abroad.
• Care continuity: Clinics provide bilingual reports to ensure local neurologists can manage ongoing care.
• Follow-up coordination: International services at specialized centers manage scheduling for virtual check-ins and refills.

Bookimed Expert Insight: While many facilities offer standard follow-up, choosing a clinic with integrated EHRs and AI like Severance Hospital is a game-changer. Their massive volume of 1.6 million outpatients yearly helps them refine remote monitoring protocols. This digital infrastructure ensures your home-country doctor receives precise data, preventing any gaps in your ALS management plan.